Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Kidney Transplant Recipients
NCT06013865Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Apr 2024
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin in chronic kidney disease (CKD), sponsored by VA Office of Research & Development. Primary endpoint: Discontinuation of Empagliflozin at 2 years. Started Apr 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06013865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013865.